Document Actions
PFS "A Benefit In The Right Context," FDA's Pazdur Says
From The Cancer Letter, Feb. 29, 2008:
The Cancer Letter asked Richard Pazdur, director of the FDA Office of Oncology Drug Products, to comment on the agency's decision last week to approve the Genentech drug Avastin for front-line treatment of metastatic breast cancer. The agency's action was something of a regulatory cliff-hanger that was watched closely by drug developers and patient advocates.
Read the interview by clicking "The Cancer Letter Archive" at left to download the Feb. 29 issue.
_____
tags:
Friday, February 29, 2008
in
drug development
| Permalink |
Comments (0)
trackback URL: http://www.cancerletter.com/tcl-blog/copy37_of_whats-going-on-with-nih/sbtrackback
Forgot your password?